Drug Trial Radar · NCT00310505
Amphotericin B Treatment in Visceral Leishmaniasis
Last checked: Nov 19, 2026Latest source record: Sep 12, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,500
Actual
Start
Jan 2003
Primary completion
Not stated
Sponsor
- Lead sponsor
- Banaras Hindu UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 4, 2006
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to assess the safety and efficacy of amphotericin B deoxycholate in doses of 0.75 mg/kg or 1.0 mg/kg for 15 doses. In each arm the drug is given in the conventional way every alternate day against the daily administration regimen being tested.
Conditions
- Visceral Leishmaniasis
Interventions
Amphotericin B deoxycholate given as daily administrationDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Final cure rate at six months after the end of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kala-azar Medical Research Center
Muzaffarpur, Bihar, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.